PALO ALTO, Calif., June 26, 2014 (GLOBE NEWSWIRE) -- Nora Therapeutics, a biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine, today announced the initiation of its Phase 2 RESPONSE Research Study of NT100 in pregnant women with a history of unexplained recurrent pregnancy loss (RPL).
Help employers find you! Check out all the jobs and post your resume.
